CBLL
CeriBell, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+54/100
Last price
24.34
▼ 0.52 (2.09%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
24.86
Day high
25.10
Day low
24.22
Volume
241.74K
Market cap
$934.12M
P/E (TTM)
—
52W range
10.85 – 25.63
Trailing performance
Returnvs SPY
1W
-2.09%
-4.0%
1M
-1.54%
-2.7%
3M
+25.46%
+20.9%
6M
+36.21%
+18.0%
YTD
+10.99%
-3.3%
1Y
+92.56%
+76.1%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CBLL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-268.78K
Net selling
Buy transactions
22
366.03K shares
Sell transactions
29
634.81K shares
Net transactions
+51
Buys less sells
Sell : buy shares
1.7 : 1
Mixed
Insider-held shares
4.54M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | CHAO XINGJUAN Chief Executive Officer |
SELL | 20.85K | $521.77K | Direct |
| Sep 15, 26 | BLUMBERG SCOTT Chief Financial Officer |
SELL | 846 | $21.15K | Direct |
| Sep 15, 26 | BLUMBERG SCOTT Chief Financial Officer |
CONVERSION | 846 | $7.96K | Direct |
| Sep 8, 26 | WOO RAYMOND Chief Technology Officer |
SELL | 4.89K | $118.90K | Direct |
| Sep 8, 26 | FOEHR DAVID Officer |
SELL | 9.26K | $224.45K | Direct |
| Sep 8, 26 | WOO RAYMOND Chief Technology Officer |
CONVERSION | 13.28K | $36.65K | Direct |
| Sep 8, 26 | FOEHR DAVID Officer |
CONVERSION | 7.50K | $35.25K | Direct |
| Sep 2, 26 | CHAO XINGJUAN Chief Executive Officer |
SELL | 39.54K | $973.08K | Direct |
| Sep 2, 26 | BLUMBERG SCOTT Chief Financial Officer |
SELL | 652 | $16.30K | Direct |
| Sep 2, 26 | CHAO XINGJUAN Chief Executive Officer |
CONVERSION | 25.00K | $117.50K | Direct |
| Sep 2, 26 | BLUMBERG SCOTT Chief Financial Officer |
CONVERSION | 652 | $6.13K | Direct |
| Aug 24, 26 | FOEHR DAVID Officer |
SELL | 1.85K | $44.42K | Direct |
| Aug 21, 26 | MANNI JOSEPH S Officer |
SELL | 1.36K | $32.69K | Direct |
| Aug 21, 26 | CHAO XINGJUAN Chief Executive Officer |
SELL | 6.07K | $145.75K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLUMBERG SCOTT |
Chief Financial Officer | 146.60K | Sale |
CHAO XINGJUAN |
Chief Executive Officer | 1.12M | Sale |
FOEHR DAVID |
Officer | 34.14K | Sale |
MANNI JOSEPH S |
Officer | 55.96K | Sale |
PARVIZI JOSEF |
Director | 2.01M | Stock Award(Grant) |
ROGERS ERICA J. |
Director | 33.05K | Stock Award(Grant) |
TAMMENOMS BAKKER JULIET |
Director | 2.50M | Stock Award(Grant) |
TAYLOR JOSEPH MICHAEL |
Director | 48.48K | Sale |
TPG GP A, L.L.C. |
Unknown | — | Sale |
WOO RAYMOND |
Chief Technology Officer | 203.12K | Sale |
Fundamentals
Market cap$934.12M
Enterprise value$826.77M
Revenue (TTM)$101.96M
Gross profit$90.64M
EBITDA$-68.80M
Net income$-66.00M
EPS (TTM)$-1.76
Free cash flow$-33.05M
Total cash$129.26M
Total debt$21.91M
Book value / share$3.36
Shares outstanding38.38M
Float26.55M
Short % of float7.27%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-15.09
PEG ratio—
Price / sales—
Price / book7.25
EV / revenue8.11
EV / EBITDA-12.02
Gross margin88.90%
Operating margin-71.11%
Profit margin-64.73%
Return on equity-43.93%
Return on assets-23.38%
Debt / equity17.08
Current ratio9.18
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $89.06M | $65.44M | $45.23M | $25.92M | +36.1% |
| Operating revenue | $89.06M | $65.44M | $45.23M | $25.92M | +36.1% |
| Cost of revenue | $10.79M | $8.69M | $7.06M | $4.43M | +24.1% |
| Gross profit | $78.27M | $56.75M | $38.16M | $21.49M | +37.9% |
| Research & development | $19.14M | $13.56M | $8.99M | $7.24M | +41.2% |
| Selling, general & admin | $117.53M | $82.90M | $59.21M | $50.27M | +41.8% |
| Total operating expense | $136.68M | $96.46M | $68.20M | $57.51M | +41.7% |
| Operating income | -$58.40M | -$39.71M | -$30.04M | -$36.02M | -47.1% |
| Net interest income | -$1.89M | -$1.99M | -$2.10M | -$1.60M | +5.1% |
| Pre-tax income | -$53.41M | -$40.45M | -$29.45M | -$37.16M | -32.0% |
| Tax provision | $0 | $0 | $11.00K | $2.00K | — |
| Net income | -$53.41M | -$40.45M | -$29.46M | -$37.16M | -32.0% |
| Net income to common | -$53.41M | -$40.45M | -$29.46M | -$37.16M | -32.0% |
| Basic EPS | -1.46 | -3.39 | -1.26 | -1.59 | +56.9% |
| Diluted EPS | -1.46 | -3.39 | -1.26 | -1.59 | +56.9% |
| EBIT | -$51.52M | -$38.46M | -$27.36M | -$35.56M | -34.0% |
| EBITDA | -$50.18M | -$37.32M | -$26.51M | -$35.06M | -34.5% |
| Basic shares | 36.54M | 11.95M | 23.32M | 23.32M | +205.8% |
| Diluted shares | 36.54M | 11.95M | 23.32M | 23.32M | +205.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $40.48M | $194.37M | $34.49M | $68.23M | -79.2% |
| Cash & short-term investments | $159.26M | $194.37M | $34.49M | $68.23M | -18.1% |
| Accounts receivable | $15.05M | $10.88M | $7.96M | $5.29M | +38.4% |
| Inventory | $7.29M | $6.94M | $5.87M | $4.08M | +5.1% |
| Total current assets | $186.72M | $217.27M | $51.96M | $79.80M | -14.1% |
| Property, plant & equipment | $4.33M | $4.45M | $3.74M | $3.87M | -2.7% |
| Total assets | $195.80M | $225.41M | $58.92M | $86.46M | -13.1% |
| Total current liabilities | $19.19M | $12.99M | $21.60M | $9.86M | +47.7% |
| Current debt | — | — | $11.83M | $2.50M | — |
| Long-term debt | $19.81M | $19.56M | — | $12.72M | +1.3% |
| Total debt | $22.28M | $21.96M | $14.20M | $18.22M | +1.4% |
| Total liabilities | $40.47M | $34.25M | $171.17M | $172.86M | +18.2% |
| Retained earnings | -$220.36M | -$166.94M | -$126.49M | -$97.03M | -32.0% |
| Shareholder equity | $155.34M | $191.16M | -$112.25M | -$86.40M | -18.7% |
| Working capital | $167.53M | $204.28M | $30.36M | $69.94M | -18.0% |
| Net tangible assets | $155.34M | $191.16M | -$112.25M | -$86.40M | -18.7% |
| Shares issued | 37.49M | 35.85M | 34.02M | 34.02M | +4.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$53.41M | -$40.45M | -$29.46M | -$37.16M | -32.0% |
| Depreciation & amortisation | $1.34M | $1.14M | $847.00K | $497.00K | +17.5% |
| Stock-based compensation | $12.22M | $5.41M | $2.68M | $7.93M | +125.9% |
| Change in working capital | $633.00K | -$3.17M | -$3.70M | -$3.88M | +120.0% |
| Operating cash flow | -$40.81M | -$35.04M | -$29.16M | -$32.00M | -16.5% |
| Capital expenditure | -$767.00K | -$1.34M | -$983.00K | -$516.00K | +42.8% |
| Investing cash flow | -$118.14M | -$1.60M | -$1.76M | -$1.40M | -7,292.8% |
| Share buybacks | — | — | $0 | -$310.00K | — |
| Financing cash flow | $5.05M | $196.52M | -$2.82M | $49.80M | -97.4% |
| Free cash flow | -$41.58M | -$36.38M | -$30.14M | -$32.52M | -14.3% |
| End cash position | $40.48M | $194.37M | $34.49M | $68.23M | -79.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $28.10M | $26.49M | $24.78M | $22.59M | $21.20M | +6.1% |
| Operating revenue | $28.10M | $26.49M | $24.78M | $22.59M | $21.20M | +6.1% |
| Cost of revenue | $2.16M | $3.37M | $3.14M | $2.65M | $2.52M | -36.0% |
| Gross profit | $25.94M | $23.12M | $21.64M | $19.94M | $18.68M | +12.2% |
| Research & development | $6.75M | $6.16M | $5.06M | $4.98M | $4.85M | +9.5% |
| Selling, general & admin | $39.17M | $37.71M | $31.18M | $29.61M | $28.78M | +3.9% |
| Total operating expense | $45.92M | $43.87M | $36.24M | $34.59M | $33.63M | +4.7% |
| Operating income | -$19.98M | -$20.75M | -$14.60M | -$14.65M | -$14.95M | +3.7% |
| Net interest income | -$438.00K | -$434.00K | -$462.00K | -$480.00K | -$477.00K | -0.9% |
| Pre-tax income | -$19.27M | -$19.74M | -$13.53M | -$13.46M | -$13.64M | +2.4% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$19.27M | -$19.74M | -$13.53M | -$13.46M | -$13.64M | +2.4% |
| Net income to common | -$19.27M | -$19.74M | -$13.53M | -$13.46M | -$13.64M | +2.4% |
| Basic EPS | -0.51 | -0.52 | -0.36 | -0.37 | -0.38 | +1.9% |
| Diluted EPS | -0.51 | -0.52 | -0.36 | -0.37 | -0.38 | +1.9% |
| EBIT | -$18.83M | -$19.30M | -$13.06M | -$12.98M | -$13.17M | +2.5% |
| EBITDA | -$18.59M | -$19.06M | -$12.77M | -$12.59M | -$12.84M | +2.5% |
| Basic shares | 38.03M | 37.66M | 37.22M | 36.81M | 36.29M | +1.0% |
| Diluted shares | 38.03M | 37.66M | 37.22M | 36.81M | 36.29M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.66M | $45.25M | $40.48M | $23.74M | $40.14M | -27.8% |
| Cash & short-term investments | $129.26M | $141.18M | $159.26M | $168.54M | $177.43M | -8.4% |
| Accounts receivable | $15.99M | $15.71M | $15.05M | $12.23M | $12.31M | +1.8% |
| Inventory | $6.74M | $6.90M | $7.29M | $6.02M | $6.00M | -2.4% |
| Total current assets | $157.85M | $168.91M | $186.72M | $191.81M | $199.79M | -6.6% |
| Property, plant & equipment | $3.54M | $3.97M | $4.33M | $3.46M | $3.76M | -10.7% |
| Total assets | $166.35M | $178.08M | $195.80M | $199.53M | $207.69M | -6.6% |
| Total current liabilities | $17.20M | $16.18M | $19.19M | $15.17M | $15.01M | +6.3% |
| Long-term debt | $19.98M | $19.92M | $19.81M | $19.75M | $19.68M | +0.3% |
| Total debt | $21.91M | $22.12M | $22.28M | $21.34M | $21.55M | -0.9% |
| Total liabilities | $38.03M | $37.27M | $40.47M | $35.44M | $35.53M | +2.1% |
| Retained earnings | -$259.36M | -$240.09M | -$220.36M | -$206.83M | -$193.36M | -8.0% |
| Shareholder equity | $128.31M | $140.81M | $155.34M | $164.08M | $172.16M | -8.9% |
| Working capital | $140.65M | $152.73M | $167.53M | $176.64M | $184.77M | -7.9% |
| Net tangible assets | $128.31M | $140.81M | $155.34M | $164.08M | $172.16M | -8.9% |
| Shares issued | 38.22M | 37.86M | 37.49M | 37.05M | 36.60M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$19.27M | -$19.74M | -$13.53M | -$13.46M | -$13.64M | — | +2.4% |
| Depreciation & amortisation | $245.00K | $239.00K | $291.00K | $391.00K | $324.00K | — | +2.5% |
| Stock-based compensation | $6.00M | $3.72M | $3.36M | $3.35M | $3.17M | — | +61.1% |
| Change in working capital | $384.00K | -$2.98M | -$382.00K | -$580.00K | $2.99M | — | +112.9% |
| Operating cash flow | -$12.86M | -$19.30M | -$10.77M | -$11.10M | -$7.53M | — | +33.3% |
| Capital expenditure | — | -$826.00K | -$179.00K | -$369.00K | — | -$279.00K | — |
| Investing cash flow | -$606.00K | $22.44M | $26.11M | -$6.94M | -$107.69M | — | -102.7% |
| Financing cash flow | $880.00K | $1.63M | $1.40M | $1.64M | $2.01M | — | -46.1% |
| Free cash flow | -$12.18M | -$20.12M | -$10.95M | -$11.47M | -$7.47M | — | +39.5% |
| End cash position | $32.66M | $45.25M | $40.48M | $23.74M | $40.14M | — | -27.8% |
Options analytics
Put / call volume
1.50
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
17.50
-28.1% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+6.2%
Puts bid over calls
Call volume
2
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
20.00
0 contracts
Heaviest put OI
17.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.46 | -0.40 | +11.9% |
| Mar 2026 | -0.39 | -0.38 | +3.6% |
| Dec 2025 | -0.41 | -0.36 | +12.7% |
| Sep 2025 | -0.41 | -0.37 | +10.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.52 | 5 | $29.16M | +29.1% |
| Next quarter | -0.43 | 5 | $31.72M | +28.0% |
| Current year | -1.96 | 5 | $115.48M | +29.7% |
| Next year | -1.61 | 5 | $147.07M | +27.4% |
Analyst targets & ownership
Mean target$28.57
High target$33.00
Low target$24.00
Implied upside17.38%
Analyst count7
ConsensusSTRONG BUY
Strong buy / Buy1 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders11.84%
Held by institutions88.31%
Institutions holding180
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
24.14
+0.83% from price
SMA 20
24.23
+0.45% from price
SMA 50
22.90
+6.27% from price
SMA 100
20.67
+17.76% from price
SMA 200
20.39
+19.35% from price
EMA 12
24.23
+0.43% from price
EMA 26
23.94
+1.66% from price
EMA 50
23.03
+5.69% from price
RSI (14)
53.5
Neutral
MACD (12,26,9)
0.29
Hist -0.10
ATR (14)
0.86
3.55% of price
Realised vol 30D
33.4%
Annualised
Bollinger upper
25.21
20, 2σ
Bollinger lower
23.25
20, 2σ
50 / 200 cross
Golden
22.90 vs 20.39
Trend bias
Above 200
+19.35%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.14
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
33.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.5%
Peak to trough
Max drawdown 5Y
-63.9%
Peak to trough
ATR 14
0.86
3.55% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
1.82M
Prior 2.10M
Change vs prior
-13.5%
Shorts covering
% of float
7.27%
Normal
% of shares out
4.74%
Against total outstanding
Days to cover
5.6
Crowded exit
Float
26.55M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Sep 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 18, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 12, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jan 28, 26 | BTIG | MAINTAINED | Buy | Buy |
| Dec 17, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 15, 25 | BTIG | MAINTAINED | Buy | Buy |
| Nov 5, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Nov 5, 25 | TD Cowen | MAINTAINED | Buy | Buy |
| Oct 21, 25 | Raymond James | INITIATED | — | Strong Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-02
Periodic Financial Reports
10-Q · 2026-05-11
Proxy Statements
DEFA14A · 2026-04-20
Corporate Changes & Voting Matters
8-K · 2026-02-24
Corporate Changes & Voting Matters
8-K · 2026-01-05
Corporate Changes & Voting Matters
8-K · 2026-01-02
Headlines
CeriBell Receives FDA Clearance for Platform Software Update
MT Newswires · 7d ago
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
GlobeNewswire · 7d ago
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
MarketBeat · 56d ago
CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ...
GuruFocus.com · 57d ago
CeriBell, Inc. Q2 2026 Earnings Call Summary
Moby · 57d ago
CeriBell (CBLL) Q2 2026 Earnings Call Transcript
Motley Fool · 57d ago
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
Zacks · 57d ago
CeriBell Q2 Earnings Call Highlights
MarketBeat · 58d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.